Upstream Bio, Inc. (UPB) stock
UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.78−0.08 (-2.80%)
Close on Nov 13, 2026Market cap $152.26MP/E –Yield –
Upstream Bio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Upstream Bio's profit margin for the twelve months ending Sep 30, 2026 was -5712.3%. For fiscal 2025 it was -5026.0%, against -2650.0% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -5026.0% | −2376.0 |
| FY2024 | Dec 31, 2024 | -2650.0% | −1787.1 |
| FY2023 | Dec 31, 2023 | -862.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -10428.4% | −5487.2 |
| Q2 FY2026 | Jun 30, 2026 | -5136.1% | −870.8 |
| Q1 FY2026 | Mar 31, 2026 | -3925.6% | +892.4 |
| Q4 FY2025 | Dec 31, 2025 | -6356.1% | −2890.9 |
| Q3 FY2025 | Sep 30, 2025 | -4941.1% | −2306.5 |
| Q2 FY2025 | Jun 30, 2025 | -4265.3% | −1387.3 |
| Q1 FY2025 | Mar 31, 2025 | -4818.0% | −3115.8 |
| Q4 FY2024 | Dec 31, 2024 | -3465.3% | −835.7 |
| Q3 FY2024 | Sep 30, 2024 | -2634.6% | −2135.1 |
| Q2 FY2024 | Jun 30, 2024 | -2878.0% | – |
| Q1 FY2024 | Mar 31, 2024 | -1702.2% | – |
| Q4 FY2023 | Dec 31, 2023 | -2629.6% | – |
| Q3 FY2023 | Sep 30, 2023 | -499.5% | – |
See a number that looks wrong?